Refractory necrotizing scleritis successfully treated with adalimumab

Necrotizing scleritis is the most severe and destructive form of scleritis with vision-threatening sequelae. It is divided into with inflammation and without inflammation (scleromalacia perforans). Adalimumab is a tumour necrosis factor (TNF)-inhibiting anti-inflammatory medication licensed for the...

Descripción completa

Detalles Bibliográficos
Autores principales: Lawuyi, Lola E., Gurbaxani, Avinash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059540/
https://www.ncbi.nlm.nih.gov/pubmed/27734292
http://dx.doi.org/10.1186/s12348-016-0107-y
_version_ 1782459424521060352
author Lawuyi, Lola E.
Gurbaxani, Avinash
author_facet Lawuyi, Lola E.
Gurbaxani, Avinash
author_sort Lawuyi, Lola E.
collection PubMed
description Necrotizing scleritis is the most severe and destructive form of scleritis with vision-threatening sequelae. It is divided into with inflammation and without inflammation (scleromalacia perforans). Adalimumab is a tumour necrosis factor (TNF)-inhibiting anti-inflammatory medication licensed for the treatment of rheumatoid and psoriatic arthritis, ankylosing spondylitis and inflammatory bowel disease (in the USA). We report two cases of necrotizing scleritis successfully treated with adalimumab.
format Online
Article
Text
id pubmed-5059540
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-50595402016-10-27 Refractory necrotizing scleritis successfully treated with adalimumab Lawuyi, Lola E. Gurbaxani, Avinash J Ophthalmic Inflamm Infect Letter to the Editor Necrotizing scleritis is the most severe and destructive form of scleritis with vision-threatening sequelae. It is divided into with inflammation and without inflammation (scleromalacia perforans). Adalimumab is a tumour necrosis factor (TNF)-inhibiting anti-inflammatory medication licensed for the treatment of rheumatoid and psoriatic arthritis, ankylosing spondylitis and inflammatory bowel disease (in the USA). We report two cases of necrotizing scleritis successfully treated with adalimumab. Springer Berlin Heidelberg 2016-10-12 /pmc/articles/PMC5059540/ /pubmed/27734292 http://dx.doi.org/10.1186/s12348-016-0107-y Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Letter to the Editor
Lawuyi, Lola E.
Gurbaxani, Avinash
Refractory necrotizing scleritis successfully treated with adalimumab
title Refractory necrotizing scleritis successfully treated with adalimumab
title_full Refractory necrotizing scleritis successfully treated with adalimumab
title_fullStr Refractory necrotizing scleritis successfully treated with adalimumab
title_full_unstemmed Refractory necrotizing scleritis successfully treated with adalimumab
title_short Refractory necrotizing scleritis successfully treated with adalimumab
title_sort refractory necrotizing scleritis successfully treated with adalimumab
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059540/
https://www.ncbi.nlm.nih.gov/pubmed/27734292
http://dx.doi.org/10.1186/s12348-016-0107-y
work_keys_str_mv AT lawuyilolae refractorynecrotizingscleritissuccessfullytreatedwithadalimumab
AT gurbaxaniavinash refractorynecrotizingscleritissuccessfullytreatedwithadalimumab

Ejemplares similares